Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Latin America held a 3% share of the market in 2025 and is expected to grow at a significant CAGR of 14% during the projection period, driven by GLP-1 medications that are driving structural health and economic shifts across Latin America by curbing surging obesity and type-2 diabetes rates, spurring vast biopharma investments, and fundamentally changing consumer habits in the fast-moving consumer goods sector
15% Patients lost an average of 15% of their body weight in ~1 year.* *In a 68-week double-blind trial studying once-weekly semaglutide injections (2.4 mg) in 1,961 patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15%, when paired with diet and exercise changes
Exposure to GLP-1 RAs was consistently associated with significantly reduced odds of SUD cases
A researcher might be in a hurry, forget to swab the top, or use the same needle for multiple vials
